

(iPS-T™: iPSC-derived T cell)
Rejuvenated and highly cytotoxic
to target tumor cells.
Easy to treat patients
with few tumor specific T cells.
A large amount of young T cells break through immuno-suppressive environment
and completely eliminate tumors.
Autologous iPS-T can be safely infused multiple times without auto-immune response.
Targeting many types of cancer antigens
with iPS-T utilizing cancer vaccines
Exhausted parental T cells
iPS-T
Red : iPS-T specific to antigen X
Green: Tumor cells NOT expressing antigen X
(iPS-T patrols but does not attack
the tumor cells)
Red : iPS-T specific to antigen X
Green: Tumor cells expressing antigen X
(iPS-T attacks and eliminates
the tumor cells)
Cell Stem Cell | (2018) 23:1–9 | https://doi.org/10.1016/j.stem.2018.10.005
CD8αβ
Strong TCR signals
for antigen specific cytotoxicity
CD8αα
Insufficient TCR signals
for antigen specific cytotoxicity
Cell Stem Cell | (2018) 23:1–9 | https://doi.org/10.1016/j.stem.2018.10.005
Elongation of iPS-T‘s telomere
Correlation between the efficacy of T cell therapy
and the telomere length is reported.
Nat Rev Cancer | (2008) 8: 299–308 | https://doi.org/10.1038/nrc2355
iPS-T‘s high ability of proliferation
Exhausted T cells do not proliferate well,
while iPS-T shows massive growth
as naïve T cells do.
Patient’s exhausted T cell
When immune checkpoint receptors on
T cells are activated, cytotoxic responses of
T cells are suppressed.
iPS-T
As iPS-T cells express no/less
immune
check points receptors,
potent cytotoxic responses
against tumor cells are regained.
NATURE COMMUNICATIONS | (2020) 11:3549 https://doi.org/10.1038/s41467-020-17175-8
Pre-vaccine
Post-vaccine
Brown dots: CD8+ T cells infiltrating
into tumor tissues
Photo:National Cancer Center Japan
T cell-derived iPSC
Rejuvenated Tcells (iPS-T)
(Grown like activated T cells:T-Blast)